A brief review of pharmacotherapeutic treatment options in smoking cessation: Bupropion versus varenicline

Journal of the American Academy of Nurse Practitioners

Volumn 22, Issue 10, 2010, Pages 557-563

  Johnson, Tam Spitzer ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Advanced practice nurse (APN); Behavior modification; Genetics; Nicotine addiction; Smoking behavior; Smoking cessation

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZAZEPINE DERIVATIVE; NICOTINE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE; VARENICLINE;

ADDICTION; BEHAVIOR THERAPY; GENETICS; HUMAN; METHODOLOGY; NURSING; REVIEW; RISK FACTOR; SMOKING; SMOKING CESSATION;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR THERAPY; BENZAZEPINES; BUPROPION; HUMANS; NICOTINE; NICOTINIC AGONISTS; QUINOXALINES; RISK FACTORS; SMOKING; SMOKING CESSATION; SUBSTANCE-RELATED DISORDERS;

EID: 78650442845     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2010.00550.x     Document Type: Review

References (28)

1. Benowitz, N. L. (1996). Pharmacology of nicotine: Addiction and therapeutics. Annual Reviews of Pharmacology Toxicology, 36, 597-613.
2. Benowitz, N. L., & Henningfield, J. E. (1994). Establishing a nicotine threshold for addiction-the implications for tobacco regulation. New England Journal of Medicine, 331, 123-125.
3. Brunnhuber, K., Cummings, K. M., Feit, S., Sherman, S., & Woodcock, J. (2007). Putting evidence into practice: Smoking cessation. BMJ Publishing Group. Retrieved January 20, 2009, from
4. Centers for Disease Control and Prevention. (2007). Cigarette smoking among adults: United States, 2006. Morbidity and Mortality Weekly Report, 56(44), 1157-1161.
5. Chantix (varenicline). (2006). Package insert. New York Pfizer.
6. Fiore, M. C., Jaen, C. R., Baker, T. B., Bailey, W. C., Bennett, G., Benowitz, N. L., et al. (2008). Treating tobacco use and dependence: 2008 Update. Clinical practice guideline. Rockville, MD U.S. Department of Health and Human Services, Public Health Service. Retrieved January 20, 2009, from
7. Goldfrank, L. R., Flomenbaum, N., Howland, M. A., Hoffman, R. S., Lewin, N. A., & Nelson, L. S. (2006). Goldfrank's toxicologic emergencies (8th ed.). New York McGraw-Hill Professional.
8. Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, M. S., et al. (2006). Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation. Journal of the American Medical Association, 296(1), 47-55.
9. Haukkala, A., Uutella, A., Vartiainen, E., Mcalister, A., & Knekt, P. (2000). Depression and smoking cessation: The role of motivation and self-efficacy. Addictive Behaviors, 25(2), 311-316.
10. Hays, J. T., & Ebbert, J. O. (2003). Bupropion for the treatment of tobacco dependence: Guidelines for balancing risks and benefits. CNS Drugs, 17(2), 71-83.
11. Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., et al. (1997). A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine, 337(17), 1195-1202.
12. Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., Williams, K. E., et al. (2006). Efficacy of varenicline, an α4β2 nicotinic acetycholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation. Journal of the American Medical Association, 296(1), 56-63.
13. Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., et al. (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine, 340(9), 685-691.
14. Kuehn, B. M. (2008). FDA warns of adverse events linked to smoking cessation drug and antiepileptics. Journal of the American Medical Association, 299(10), 1121-1122.
15. Li, M. D. (2003). The genetics of smoking related behavior: A brief review. American Journal of the Medical Sciences, 326(4), 168-173.
16. Meredith, L. S., Yano, E. M., Hickey, S. C., & Sherman, S. E. (2005). Primary care provider attitudes are associated with smoking cessation counseling and referral. Medical Care, 43(9), 929-934.
17. Oncken, C., Gonzales, D., Nides, M., Rennard, S., Watsky, E., Billing, C., et al. (2006). Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine, 166, 1571-1577.
18. Pleis, J. R., & Lethbridge-Cejku, M. (2007). Summary of health statistics for U.S. adults: National health interview survey, 2006. National Center for health Statistics. Vital Health Stat, 10(235), 1-153.
19. Potts, L. A., & Garwood, C. L. (2007). Varenicline: The newest agent for smoking cessation. American Journal of Health-System Pharmacy, 64, 1381-1384.
20. Rossing, M. A. (1998). Genetic influences on smoking: Candidate genes. Environmental Health Perspectives, 106(5), 231-238.
21. Sullivan, P. F. & Kendler, K. S. (1999). The genetic epidemiology of smoking. Nicotine and Tobacco Research, 1, S51-S57.
22. Sullivan, K. M., Seed, S. M., & DeBellis, R. J. (2007). Smoking cessation: A review of treatment consideration. American Journal of Lifestyle Medicine, 1, 201-213.
23. Tonneson, P., Tonstad, S., Hjalmarson, A., Lebargy, F., Spiegel, P. I. V., Hider, A., et al. (2003). A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. Journal of Internal Medicine, 254, 184-192.
24. Tonstad, S., Tonneson, P., Hajek, P., Williams, K. E., Billing, C. B., & Reeves, K. R. (2006). Effect of maintenance therapy with varenicline on smoking cessation. Journal of the American Medical Association, 296(1), 64-71.
25. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. (2001). Women and smoking. A report of the Surgeon General. Washington, DC U.S. Government Printing Office.
26. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. (2004). The health consequences of smoking: A report of the Surgeon General. Washington, DC U.S. Government Printing Office.
27. Warner, C., & Shoaib, M. (2006). How does bupropion work as a smoking cessation aid. Addiction Biology, 10(3), 219-231.
28. Wu, P., Kumanan, W., Popey, D., & Edward, J. M. (2006). Effectiveness of smoking cessation therapies: A systematic review and meta-analysis. BMC Public Health, 6(300). doi: